PLAINSBORO, N.J.– Novo Nordisk, the maker of the widely popular weight-loss and diabetes drugs Wegovy and Ozempic, has reduced prices for most versions of these medications. As of November 17, the monthly cost for injectable Wegovy and Ozempic is now $349, down from $499, for customers purchasing directly from the company, through telehealth partners, or at retail pharmacies. The 2 mg dose of Ozempic will remain at $499 per month.
New customers can also take advantage of an introductory offer: the 0.25 mg and 0.5 mg doses of Wegovy and Ozempic will cost $199 per month for the first two months. This promotion is available to self-pay consumers through March 31, 2026.
The company reduced its prices following pressure from the Trump administration, which urged the company and competitor Eli Lilly to lower the cost of widely used weight-loss and diabetes drugs.
Novo Nordisk continues to face pressure from compounding pharmacies that offer discounted, unauthorized versions of "semaglutide" — the active ingredient in its flagship drugs, Wegovy and Ozempic.
